Nanjing Leads Biolabs Co.,ltd

This early-stage study tested a new drug called LBL-019, given alone or with an existing immunotherapy, in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatment showed any early signs of h…

This early-stage study tested the safety of a new three-drug combination (LBL-007, toripalimab, and axitinib) for people with advanced melanoma that cannot be removed by surgery. The main goal was to find the highest safe dose and see what side effects occurred. Researchers also …